LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Your last searches

  1. AU="Gee, Bruce"
  2. AU="Baogang Sun"
  3. AU="Suszycki, L"
  4. AU="Edward G. Clark"
  5. AU="Regan, Anthony"
  6. AU="Hammoudi Halat, Dalal"
  7. AU="Lanata, Claudio F"
  8. AU="Bao, Ho The"
  9. AU="Morin, Cory W"
  10. AU="Deniskina, N."
  11. AU="Filipović, Nenad R"
  12. AU="Stülke, Jörg"
  13. AU="Tran Kiem, Cécile"
  14. AU="Trivedi, Pritesh S"
  15. AU="Seemann, Stefan E"
  16. AU="Lotfi Chouchane"
  17. AU="Fay, Bianca"
  18. AU="Dahlke, Marc-H"
  19. AU="Foell, Jens"
  20. AU="Bruno Alessandro Rivieccio"
  21. AU="Cristea, Alexandra I"
  22. AU="Sakr, Hader I"
  23. AU="Shikora, Scott A."
  24. AU="Raza Naqvi"
  25. AU="Chin Fatt, Cherise R"
  26. AU="Leena Sahlström"
  27. AU="Karkare, Siddharth"
  28. AU="Corrêa, Diogo G"
  29. AU="Choi, Sun Ha"

Search results

Result 1 - 8 of total 8

Search options

  1. Article: Beyond Poiseuille flow: A transient energy-conserving model for flow through fractures of varying aperture

    Gee, Bruce / Gracie, Robert

    Advances in water resources. 2022 June, v. 164

    2022  

    Abstract: Large-scale models of fluid flow through fractures are almost exclusively based on Poiseuille flow (the cubic law). When the fracture aperture is time and/or spatially varying, flow is transient, and/or flow rates are modest (Re≥1), Poiseuille flow ... ...

    Abstract Large-scale models of fluid flow through fractures are almost exclusively based on Poiseuille flow (the cubic law). When the fracture aperture is time and/or spatially varying, flow is transient, and/or flow rates are modest (Re≥1), Poiseuille flow predictions can deviate substantially from the full Navier–Stokes solution and generally do not satisfy conservation of energy. A new Reduced Dimension Fracture Flow (RDFF) model is derived which more accurately predicts transient fracture flow for incompressible fluids with modest Reynolds numbers. The RDFF model is derived from the two-dimensional Navier–Stokes equations and yields a two-field model (fluid flux and pressure) governed by conservation of mass and momentum. The RDFF model conserves energy and is shown to include both Poiseuille flow and Forchheimer flow as limiting cases. The performance of the RDFF model is compared to the existing Poiseuille flow model and the solution to the full Navier–Stokes equations in three benchmarks problems. The RDFF model demonstrates complex transient and inertial behaviours not previously captured and produces up to 400% improvements in error over Poiseuille flow in steady-state flow conditions for 1≤Re≤100. The RDFF model is demonstrated to be superior in application where the Reynold’s number is modest and when aperture varies in space and/or time.
    Keywords energy ; models ; momentum ; water
    Language English
    Dates of publication 2022-06
    Publishing place Elsevier Ltd
    Document type Article
    ZDB-ID 2023320-6
    ISSN 1872-9657 ; 0309-1708
    ISSN (online) 1872-9657
    ISSN 0309-1708
    DOI 10.1016/j.advwatres.2022.104192
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

  2. Article: Seborrhoeic dermatitis.

    Gee, Bruce C

    Clinical evidence

    2004  , Issue 12, Page(s) 2344–2352

    MeSH term(s) Dermatitis, Seborrheic/drug therapy ; Humans ; Imidazoles/therapeutic use ; Ketoconazole/therapeutic use ; Scalp Dermatoses/drug therapy ; Selenium Compounds/therapeutic use
    Chemical Substances Imidazoles ; Selenium Compounds ; bifonazole (QYJ305Z91O) ; Ketoconazole (R9400W927I) ; selenium disulfide (Z69D9E381Q)
    Language English
    Publishing date 2004-12
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 1495368-7
    ISSN 1462-3846
    ISSN 1462-3846
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Virtual consultation for actinic keratosis.

    Dhariwal, Sukhjit / Hari, Tushar / Kaur, Kamal / Thind, Chamandeep / Bedlow, Alison / Gee, Bruce C / Tso, Simon

    BJGP open

    2020  Volume 4, Issue 4

    Language English
    Publishing date 2020-10-27
    Publishing country England
    Document type Journal Article
    ISSN 2398-3795
    ISSN (online) 2398-3795
    DOI 10.3399/bjgpopen20X101126
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Geometric cutaneous melanoma: a helpful clinical sign of malignancy?

    Morris, Andrew D / Gee, Bruce C / Millard, Leslie G

    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.

    2003  Volume 29, Issue 8, Page(s) 827–8; discussion 829

    Abstract: Background: Malignant melanomas change shape in a random pattern, with ovoid, crescentic, or nodular shapes seen most frequently. We have observed a number of malignant melanomas that have presented with a geometric, angular shape and have noted that ... ...

    Abstract Background: Malignant melanomas change shape in a random pattern, with ovoid, crescentic, or nodular shapes seen most frequently. We have observed a number of malignant melanomas that have presented with a geometric, angular shape and have noted that pigmented lesions with this configuration are often found to be malignant. We present 20 patients with malignant melanoma whose lesion displayed a geometric, angular shape.
    Methods: Before excision for formal histopathology, all lesions were scored using the seven-point checklist and ABCDE systems and were divided into low-risk or significant risk of melanoma.
    Results: Five different geometric shapes were observed. Depending on the scoring system employed, 20% to 40% of the geometric melanomas were considered to be of low risk of malignancy.
    Conclusion: The development of geometrical angular patterns in a malignant melanoma may represent a morphologic growth pattern that can be used as a clinical risk sign. Even apparently benign low-risk lesions with a geometric shape may pose a significant risk of malignant melanoma. By definition, the majority of lesions that are morphologically geometric are symmetrical in shape, which is more in favor of a benign diagnosis. This may increase the likelihood that early cutaneous melanomas with a geometric shape may be missed. Any pigmented lesion with a geometric configuration should raise the clinician's suspicion of malignancy even if considered otherwise to be of low risk by the standard melanoma checklists.
    MeSH term(s) Humans ; Melanoma/diagnosis ; Risk Assessment ; Skin Neoplasms/diagnosis
    Language English
    Publishing date 2003-06-10
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1227586-4
    ISSN 1524-4725 ; 1076-0512
    ISSN (online) 1524-4725
    ISSN 1076-0512
    DOI 10.1046/j.1524-4725.2003.29216.x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Asymptomatic nodules on the foot--quiz case.

    Goulding, Jonathan M R / Knowlson, Louise E / Carr, Richard A / Gee, Bruce C

    Archives of dermatology

    2009  Volume 145, Issue 11, Page(s) 1325–1330

    MeSH term(s) Biopsy, Needle ; Cumulative Trauma Disorders/complications ; Follow-Up Studies ; Foot Dermatoses/etiology ; Foot Dermatoses/pathology ; Foot Diseases/etiology ; Foot Diseases/pathology ; Humans ; Immunohistochemistry ; Male ; Severity of Illness Index ; Skin/pathology ; Young Adult
    Language English
    Publishing date 2009-11
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 212139-6
    ISSN 1538-3652 ; 0003-987X
    ISSN (online) 1538-3652
    ISSN 0003-987X
    DOI 10.1001/archdermatol.2009.254-a
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: A rare, rapidly growing purple tumor on the cheek. Chondroid syringoma.

    Gee, Bruce C / Morris, Andrew D / Kaye, Philip / Varma, Sandeep

    Archives of dermatology

    2004  Volume 140, Issue 6, Page(s) 751–756

    MeSH term(s) Adenoma, Pleomorphic/diagnosis ; Adenoma, Pleomorphic/pathology ; Adenoma, Pleomorphic/surgery ; Adult ; Diagnosis, Differential ; Face ; Humans ; Male ; Sweat Gland Neoplasms/diagnosis ; Sweat Gland Neoplasms/pathology ; Sweat Gland Neoplasms/surgery
    Language English
    Publishing date 2004-06
    Publishing country United States
    Document type Case Reports ; Journal Article
    ZDB-ID 212139-6
    ISSN 1538-3652 ; 0003-987X
    ISSN (online) 1538-3652
    ISSN 0003-987X
    DOI 10.1001/archderm.140.6.751-b
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Herbal is not synonymous with safe.

    Gee, Bruce C / Wilson, Penny / Morris, Andrew D / Emerson, Russell M

    Archives of dermatology

    2002  Volume 138, Issue 12, Page(s) 1613

    MeSH term(s) Cohort Studies ; Consumer Product Safety ; Eczema/diagnosis ; Eczema/drug therapy ; Female ; Health Knowledge, Attitudes, Practice ; Humans ; Male ; Patient Education as Topic ; Phytotherapy/adverse effects ; Phytotherapy/methods ; Plant Extracts/adverse effects ; Plant Extracts/therapeutic use ; Plants, Medicinal ; Psoriasis/diagnosis ; Psoriasis/drug therapy ; Risk Assessment ; Surveys and Questionnaires ; United Kingdom
    Chemical Substances Plant Extracts
    Language English
    Publishing date 2002-11-26
    Publishing country United States
    Document type Comparative Study ; Letter ; Comment
    ZDB-ID 212139-6
    ISSN 1538-3652 ; 0003-987X
    ISSN (online) 1538-3652
    ISSN 0003-987X
    DOI 10.1001/archderm.138.12.1613
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.

    Corrie, P G / Marshall, A / Nathan, P D / Lorigan, P / Gore, M / Tahir, S / Faust, G / Kelly, C G / Marples, M / Danson, S J / Marshall, E / Houston, S J / Board, R E / Waterston, A M / Nobes, J P / Harries, M / Kumar, S / Goodman, A / Dalgleish, A /
    Martin-Clavijo, A / Westwell, S / Casasola, R / Chao, D / Maraveyas, A / Patel, P M / Ottensmeier, C H / Farrugia, D / Humphreys, A / Eccles, B / Young, G / Barker, E O / Harman, C / Weiss, M / Myers, K A / Chhabra, A / Rodwell, S H / Dunn, J A / Middleton, M R / Nathan, Paul / Lorigan, Paul / Dziewulski, Peter / Holikova, Sonja / Panwar, Udaiveer / Tahir, Saad / Faust, Guy / Thomas, Anne / Corrie, Pippa / Sirohi, Bhawna / Kelly, Charles / Middleton, Mark / Marples, Maria / Danson, Sarah / Lester, James / Marshall, Ernest / Ajaz, Mazhar / Houston, Stephen / Board, Ruth / Eaton, David / Waterston, Ashita / Nobes, Jenny / Loo, Suat / Gray, Gill / Stubbings, Helen / Gore, Martin / Harries, Mark / Kumar, Satish / Goodman, Andrew / Dalgleish, Angus / Martin-Clavijo, Agustin / Marsden, Jerry / Westwell, Sarah / Casasola, Richard / Chao, David / Maraveyas, Anthony / Patel, Poulam / Ottensmeier, Christian / Farrugia, David / Humphreys, Alison / Eccles, Bryony / Dega, Renata / Herbert, Chris / Price, Christopher / Brunt, Murray / Scott-Brown, Martin / Hamilton, Joanna / Hayward, Richard Larry / Smyth, John / Woodings, Pamela / Nayak, Neena / Burrows, Lorna / Wolstenholme, Virginia / Wagstaff, John / Nicolson, Marianne / Wilson, Andrew / Barlow, Clare / Scrase, Christopher / Podd, Timothy / Gonzalez, Michael / Stewart, John / Highley, Martin / Grumett, Simon / Talbot, Toby / Nathan, Kannon / Coltart, Robert / Gee, Bruce

    Annals of oncology : official journal of the European Society for Medical Oncology

    2018  Volume 29, Issue 8, Page(s) 1843–1852

    Abstract: Background: Bevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor shown to improve survival in advanced solid cancers. We evaluated the role of adjuvant bevacizumab in melanoma patients at high risk of ... ...

    Abstract Background: Bevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor shown to improve survival in advanced solid cancers. We evaluated the role of adjuvant bevacizumab in melanoma patients at high risk of recurrence.
    Patients and methods: Patients with resected AJCC stage IIB, IIC and III cutaneous melanoma were randomised to receive either adjuvant bevacizumab (7.5 mg/kg i.v. 3 weekly for 1 year) or standard observation. The primary end point was detection of an 8% difference in 5-year overall survival (OS) rate; secondary end points included disease-free interval (DFI) and distant metastasis-free interval (DMFI). Tumour and blood were analysed for prognostic and predictive markers.
    Results: Patients (n=1343) recruited between 2007 and 2012 were predominantly stage III (73%), with median age 56 years (range 18-88 years). With 6.4-year median follow-up, 515 (38%) patients had died [254 (38%) bevacizumab; 261 (39%) observation]; 707 (53%) patients had disease recurrence [336 (50%) bevacizumab, 371 (55%) observation]. OS at 5 years was 64% for both groups [hazard ratio (HR) 0.98; 95% confidence interval (CI) 0.82-1.16, P = 0.78). At 5 years, 51% were disease free on bevacizumab versus 45% on observation (HR 0.85; 95% CI 0.74-0.99, P = 0.03), 58% were distant metastasis free on bevacizumab versus 54% on observation (HR 0.91; 95% CI 0.78-1.07, P = 0.25). Forty four percent of 682 melanomas assessed had a BRAFV600 mutation. In the observation arm, BRAF mutant patients had a trend towards poorer OS compared with BRAF wild-type patients (P = 0.06). BRAF mutation positivity trended towards better OS with bevacizumab (P = 0.21).
    Conclusions: Adjuvant bevacizumab after resection of high-risk melanoma improves DFI, but not OS. BRAF mutation status may predict for poorer OS untreated and potential benefit from bevacizumab.
    Clinical trial information: ISRCTN 81261306; EudraCT Number: 2006-005505-64.
    MeSH term(s) Adolescent ; Adult ; Aged ; Aged, 80 and over ; Bevacizumab/administration & dosage ; Chemotherapy, Adjuvant/methods ; Dermatologic Surgical Procedures ; Disease-Free Survival ; Drug Administration Schedule ; Female ; Follow-Up Studies ; Humans ; Male ; Melanoma/mortality ; Melanoma/pathology ; Melanoma/therapy ; Middle Aged ; Mutation ; Neoplasm Recurrence, Local/epidemiology ; Neoplasm Recurrence, Local/prevention & control ; Neoplasm Staging ; Proto-Oncogene Proteins B-raf/genetics ; Skin Neoplasms/mortality ; Skin Neoplasms/pathology ; Skin Neoplasms/therapy ; Survival Analysis ; Time Factors ; Watchful Waiting ; Young Adult
    Chemical Substances Bevacizumab (2S9ZZM9Q9V) ; BRAF protein, human (EC 2.7.11.1) ; Proto-Oncogene Proteins B-raf (EC 2.7.11.1)
    Language English
    Publishing date 2018-11-01
    Publishing country England
    Document type Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
    ZDB-ID 1025984-3
    ISSN 1569-8041 ; 0923-7534
    ISSN (online) 1569-8041
    ISSN 0923-7534
    DOI 10.1093/annonc/mdy229
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top